Home/Pipeline/NA-911

NA-911

Stroke

Phase 2AActive

Key Facts

Indication

Stroke

Phase

Phase 2A

Status

Active

Company

Biomed

About Biomed

Biomed Industries is a late-stage private biotech with a broad and advanced pipeline targeting major neurodegenerative, metabolic, and cardiovascular diseases. Its core strategy is underpinned by a proprietary 'Unified Acceleration Platform,' a theoretical and AI-driven framework positing shared biological dysfunctions across these disease areas. The company has multiple Phase 2 and Phase 3 assets, most notably NA-931 for obesity and NA-831 for Alzheimer's, and one FDA-approved device, the MICROS Infusion System.

View full company profile

Therapeutic Areas

Neurological Diseases Metabolic Disorders Cardiovascular Diseases Rare Diseases

Other Stroke Drugs

Drug	Company	Phase	Status
NOX4 Inhibitor Platform	Glucox Biotech	Research	Active
LG3	Stream Biomedical	Pre-clinical	Active
Patient Transport Optimization	Zeto	Research	Active
DIASTROKE	Diagenics	Development/Commercial	Active
APOSEC	Aposcience	Pre-clinical	Active
NXL-001	NeuExcell Therapeutics	Phase 1	Active
Precision Neuromodulation for Stroke Recovery	Panaxium	Pre-clinical	Active
Autologous Wnt-activated ADSC Therapy	Regeneration Biomedical	Pre-clinical	Active
NaviFUS Neuromodulation for Stroke Rehabilitation	NaviFUS	Phase 1	Active
Banked Cord Blood Stem Cells	Cryo-Cell	Clinical Trials	Investigational